miRNA in Parkinson's disease: From pathogenesis to theranostic approaches

microRNA (miRNA) is a non-coding RNA type, regulating gene expressions at a post-transcriptional level. Changes in miRNA expressions can cause problems such as lipid metabolism disorder, cardiovascular disease, growth retardation, low birth weight and insulin resistance, etc., in human and animals. In this study, we investigated the evolutionary relationships of 14 miRNAs including hsa-miR27a-5p, hsa-miR149-3p, hsa-miR374c-5p, mmu-miR-678, mmu-miR-698-5p, hsa-miR-199a-3p, hsa-miR122-3p, hsa-miR342-3p, mmu-miR201-5p, hsa-miR429, hsa-miR370-3p, hsa-miR130a-5p, hsa-miR330-3p and hsa-miR770-5p related to different metabolic pathways including cardiovascular diseases and lipid metabolism. For this purpose, miRNAs were retrieved from miRBase database. After, Clustal Omega analyses were performed for alignment, and a phylogenetic tree was constructed via MEGA 11. Phylogenetic tree indicated that 14 miRNA sequences were clustered into four groups. One group consisted of mmu-miR-678, and the other 13 sequences were separated into three groups, revealing a close relationship among miRNAs. Findings from different studies provide a new perspective for potential miRNA-based biomarkers to detect lipid metabolism disorders, cardiovascular diseases as well as related disorders.

show abstract

“…There are many different studies to identify miRNA and disease relationships [27][28][29]. miR678 analysed in this study is one of them.…”

Section: Discussionmentioning

confidence: 99%

The evolutionary relationships of microRNAs in the regulation of glucose and lipid metabolism in human and animals

Kılıç

Marakli

2023

IJPTE

View full text Add to dashboard Cite

show abstract

“…For example, Li et al (203) showed that AKT-mediated FoxO1 inactivation increases pathogenic mutant Huntington (mHtt) protein aggregates, yet another study showed that increasing FoxO1-dependent expression of autophagy, mitochondrial, and antioxidants genes improves HD symptoms including increased neuronal survival and enhanced motor control (204). Most studies of PD demonstrate that increased FoxO1 contributes to its pathology via increased inflammation and apoptosis (205,206). Evidence also suggests that FoxO1 mediates the depressive symptoms of PD (207).…”

Section: Foxo1 and T2dbrainmentioning

confidence: 99%

FoxO1 as a tissue-specific therapeutic target for type 2 diabetes

Teaney,

Cyr

2023

Front. Endocrinol.

View full text Add to dashboard Cite

Forkhead box O (FoxO) proteins are transcription factors that mediate many aspects of physiology and thus have been targeted as therapeutics for several diseases including metabolic disorders such as type 2 diabetes mellitus (T2D). The role of FoxO1 in metabolism has been well studied, but recently FoxO1’s potential for diabetes prevention and therapy has been debated. For example, studies have shown that increased FoxO1 activity in certain tissue types contributes to T2D pathology, symptoms, and comorbidities, yet in other tissue types elevated FoxO1 has been reported to alleviate symptoms associated with diabetes. Furthermore, studies have reported opposite effects of active FoxO1 in the same tissue type. For example, in the liver, FoxO1 contributes to T2D by increasing hepatic glucose production. However, FoxO1 has been shown to either increase or decrease hepatic lipogenesis as well as adipogenesis in white adipose tissue. In skeletal muscle, FoxO1 reduces glucose uptake and oxidation, promotes lipid uptake and oxidation, and increases muscle atrophy. While many studies show that FoxO1 lowers pancreatic insulin production and secretion, others show the opposite, especially in response to oxidative stress and inflammation. Elevated FoxO1 in the hypothalamus increases the risk of developing T2D. However, increased FoxO1 may mitigate Alzheimer’s disease, a neurodegenerative disease strongly associated with T2D. Conversely, accumulating evidence implicates increased FoxO1 with Parkinson’s disease pathogenesis. Here we review FoxO1’s actions in T2D conditions in metabolic tissues that abundantly express FoxO1 and highlight some of the current studies targeting FoxO1 for T2D treatment.

show abstract

“…The presence of genetic material, such as miRNAs, is one of the largest common contents of exosomes [ 74 ]. Disorders like PD exhibit considerable disruption in gene expression, especially at the miRNA level [ 182 , 183 ]. Exosomes derived from MSCs can transfer miRNAs to neuronal cells.…”

Section: Msc-evs In Parkinson’s Diseasesmentioning

confidence: 99%

Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities

et al. 2023

View full text Add to dashboard Cite

Mesenchymal stem cells (MSCs) are a type of versatile adult stem cells present in various organs. These cells give rise to extracellular vesicles (EVs) containing a diverse array of biologically active elements, making them a promising approach for therapeutics and diagnostics. This article examines the potential therapeutic applications of MSC-derived EVs in addressing neurodegenerative disorders such as Alzheimer’s disease (AD), multiple sclerosis (MS), Parkinson’s disease (PD), amyotrophic lateral sclerosis (ALS), and Huntington’s disease (HD). Furthermore, the present state-of-the-art for MSC-EV-based therapy in AD, HD, PD, ALS, and MS is discussed. Significant progress has been made in understanding the etiology and potential treatments for a range of neurodegenerative diseases (NDs) over the last few decades. The contents of EVs are carried across cells for intercellular contact, which often results in the control of the recipient cell’s homeostasis. Since EVs represent the therapeutically beneficial cargo of parent cells and are devoid of many ethical problems connected with cell-based treatments, they offer a viable cell-free therapy alternative for tissue regeneration and repair. Developing innovative EV-dependent medicines has proven difficult due to the lack of standardized procedures in EV extraction processes as well as their pharmacological characteristics and mechanisms of action. However, recent biotechnology and engineering research has greatly enhanced the content and applicability of MSC-EVs.

show abstract

miRNA in Parkinson's disease: From pathogenesis to theranostic approaches

Cited by 14 publications

References 227 publications

The evolutionary relationships of microRNAs in the regulation of glucose and lipid metabolism in human and animals

The evolutionary relationships of microRNAs in the regulation of glucose and lipid metabolism in human and animals

FoxO1 as a tissue-specific therapeutic target for type 2 diabetes

Mesenchymal Stem Cell-Derived Extracellular Vesicles: An Emerging Diagnostic and Therapeutic Biomolecules for Neurodegenerative Disabilities

Contact Info

Product

Resources

About